Insider buying last 90 days
No open-market insider purchases were filed for IBRX in the last 90 days.
From Form 4 filings, dated to when each was filed.
Nov 13 close
ImmunityBio fell 17.7% this week after third-quarter results showed product revenue up 53% year-over-year to $48.7 million, with first nine months U.S. revenue up 92% to $143.6 million, but the quarterly figure missed Wall Street's estimate and came in below the prior quarter. The company reported a loss of $0.22 per share against a $0.08 estimate, compared with a $0.07 loss a year earlier, and disclosed "substantial doubt" about its ability to continue without additional funding. Alongside the earnings, ImmunityBio announced an expanded FDA approval for ANKTIVA in combination with BCG for BCG-unresponsive non-muscle invasive bladder cancer, and reported that the ANKTIVA plus BCG combination met the primary efficacy endpoint in the QUILT-2.005 trial for BCG-naïve non-muscle invasive bladder cancer.
Shares closed at $7.11, between the 50-day average of $8.72 and the 200-day average of $7.96, with one-month returns down 32.4% and six-month returns down 12.3%, against a one-year return of 235.4%. The GekkoIndex reads 66.7, placing the stock in the Accumulation zone, and the price sits 34.7% below the Gekko Fair Value of $10.89.
The next earnings date is 2 March 2027, 99 days away, outside a typical 20-trading-day hold. Over the last 90 days, Congress recorded 2 buys and 0 sells, and one trailblazer holder is noted. Seasonally, the next 20 trading days have averaged -4.5% over 5 years, rising in 3 of them, a contrast worth noting against the current Accumulation reading. Analyst coverage from 4 firms is unanimously rated buy, with a consensus target of $14.25.
Written by AI from the Nov 9, 2026 close and checked automatically against the figures on this page.
ImmunityBio scores 4 supportive, 2 mixed and 0 headwinds across the 6 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
4 supportive2 mixed0 headwinds
Averages disagree
Close $6.02 sits between the 50-day ($8.59) and 200-day ($7.97) averages, or the averages disagree.
See the chart70.9, Buying
Reading 70.9 is in the Buying zone.
See the GekkoIndex42.8% below
Price is 42.8% below Gekko Fair Value (more than 5% below).
See fair valueLeans bullish
Last 90 days: Congress 2 buys / 0 sales.
See smart moneyReports in 99 days
Next report Feb 22, 2027, 99 days away — outside a typical 20-trading-day hold.
See earnings−6.9% on average
From this point in the calendar, the next 20 trading days averaged −6.9% over 5 years, rising in 3 of them.
See seasonalityA description of current data, not a recommendation. How this page works
ImmunityBio closed at $6.02 on Nov 13, 2026, +192.2% over the past year, inside a 52-week range of $1.95 to $12.43.
Use the left and right arrow keys to read daily values.
Put IBRX on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
ImmunityBio works on medicines still in clinical testing, aimed at cancer and infectious disease. It builds its work around a range of immune-based approaches, including antibody-cytokine fusion proteins, engineered immunomodulators, vaccine technologies, natural killer cell therapies, and methods that engage the body's T-cell response. Several of its treatment candidates have reached Phase II or III trials, targeting tumors such as bladder, pancreatic, and lung cancer, along with pathogens like SARS-CoV-2 and HIV.
The company pursues its research partly through outside collaboration, working with organizations such as the National Cancer Institute and the National Institute of Deafness and Communication Disorders, as well as Amyris. It also holds licensing agreements with a number of firms, among them CytRx, EnGeneIC, GlobeImmune, the Infectious Disease Research Institute, Sanford Health, Shenzhen Beike Biotechnology, Sorrento Therapeutics, and Viracta Therapeutics, reflecting a network of shared research and technology arrangements rather than a single in-house pipeline.
ImmunityBio was founded in 2014 and is based in San Diego, California. Its shares are listed on the NASDAQ under the ticker IBRX.
ImmunityBio’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 70.9, in the Buying zone, up 11.4 points over five sessions.
Up 11.4 points over five sessions, from the Neutral zone.
Reading for Nov 13, 2026
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying (current zone) | 44 | +2.7% | +10.2% | ||
| Accumulation | 262 | +2.8% | +14.5% | ||
| Neutral | 352 | +0.8% | +1.3% | ||
| Distribution | 37 | +3.3% | +4.5% | ||
| Selling | 7 | Too few readings yet | |||
Average IBRX share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Buying readings averaged +2.9% over 20 days. Past behaviour doesn’t guarantee future results.
Buying zone: Smart money likely accumulating heavily. About the five zones →
ImmunityBio trades 42.8% below Gekko Fair Value of $10.53, so the shares are undervalued on Gekko’s estimate.
Gekko’s own estimate of what ImmunityBio shares are worth, recalculated every trading day.
$10.53
Gekko Fair Value, Nov 14, 2026
42.8% Undervalued
At the end of Aug 2026 the price was 28.0% below the estimate.
No open-market insider purchases were filed for ImmunityBio, and members of Congress disclosed 2 purchases and 0 sales, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
No open-market insider purchases were filed for IBRX in the last 90 days.
From Form 4 filings, dated to when each was filed.
2trades disclosed: 2 purchases and 0 sales.
| Member | Amount | Disclosed |
|---|---|---|
| Lisa McClain House, MI, purchase | $1,001 - $15,000 | Oct 12 traded Sep 30 |
| Lisa McClain House, MI, purchase | $1,001 - $15,000 | Oct 12 traded Sep 28 |
From congressional disclosures, which report amounts as ranges.
ImmunityBio has been buying back its own shares.
From company filings.
0of the funds Gekko tracks hold IBRX.
ImmunityBio reports on Feb 22, 2027 (99 days away), and beat the EPS estimate in 5 of its last 8 reports.
Feb 22, 2027
99 days away
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Aug 4, 2026 | −$0.22 est −$0.08 | $51.24M est $49.70M | +1.4% |
| May 7, 2026 | −$0.08 est −$0.07 | $44.21M est $43.07M | +1.6% |
| Feb 23, 2026 | −$0.06 est −$0.11 | $38.29M est $38.36M | +32.8% |
| Nov 4, 2025 | −$0.07 est −$0.10 | $32.06M est $37.78M | −4.9% |
| Aug 5, 2025 | −$0.10 est −$0.10 | $26.43M est $31.88M | −1.2% |
| May 12, 2025 | −$0.15 est −$0.16 | $16.52M est $16.60M | +21.3% |
| Mar 3, 2025 | −$0.08 est −$0.13 | $7.55M est $9.63M | −8.2% |
| Nov 12, 2024 | −$0.12 est −$0.18 | $6.11M est $9.07M | −11.4% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Analysts’ average 12-month price target for ImmunityBio is $14.25, +136.7% from the last close, from 4 firms rating the stock in the last 90 days.
Each firm’s latest rating in the last 90 days: 4 firms.
| Date | Firm | Target | vs price |
|---|---|---|---|
| Nov 9 | H.C. Wainwright | $15 | +149.2% |
| Nov 9 | BTIG | $12 | +99.3% |
| Oct 29 | BTIG | $12 | +99.3% |
| Oct 15 | H.C. Wainwright | $15 | +149.2% |
| Oct 14 | Piper Sandler | $16 | +165.8% |
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Over the next 20 trading days from Nov 14, ImmunityBio averaged −6.9% across the last 5 years, rising in 3 of them.
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | −5.3% | 2 of 5 |
| Next 10 trading days | +4.0% | 4 of 5 |
| Next 15 trading days | −3.5% | 2 of 5 |
| Next 20 trading days | −6.9% | 3 of 5 |
| Next 30 trading days | −8.2% | 1 of 5 |
For scale, IBRX’s typical 20-trading-day move in either direction is about 14.8%.
ImmunityBio’s market cap is $6.40B and revenue of $182.6M over the last twelve months.
Coverage of ImmunityBio this week reads positive: 7 positive, 4 neutral and 3 negative headlines.
ImmunityBio’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| LLYEli Lilly | Neutral | 24.0% above |
| JNJJohnson & Johnson | Neutral | 4.4% above |
| ABBVAbbVie | Neutral | 23.7% above |
| MRKMerck | Neutral | 8.2% below |
| AZNAstraZeneca | Neutral | 34.6% below |
| PFEPfizer | Accumulation | 8.9% below |
A peer links to its own page where one exists.
ImmunityBio’s market cap is $6.40B at the Nov 13, 2026 close of $6.02, with 1.06B shares outstanding.
The consensus analyst 12-month price target for ImmunityBio is $14.25, +136.7% from the last close. Of the 4 firms that rated the stock in the last 90 days, 4 rate it a buy, 0 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
On Gekko’s estimate ImmunityBio is undervalued: the Nov 13, 2026 close of $6.02 is 42.8% below Gekko Fair Value of $10.53. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
ImmunityBio is expected to report on Feb 22, 2027 (99 days away). Analysts expect earnings of −$0.14 per share on revenue of $56.73M. ImmunityBio beat the earnings estimate in 5 of its last 8 reports, moving 10.4% on average across the report.
ImmunityBio’s 52-week high is $12.43 and its 52-week low is $1.95; it closed at $6.02 on Nov 13, 2026, +192.2% over the past year.
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 4 of the 6 items with data read as supportive (gekkoindex, fair value, smart money and earnings risk), 2 as mixed (trend and seasonality). The checklist is a description of current data, not a recommendation.
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,475 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.Type a ticker or company name. Press Esc to close.